MOLN Stock Overview
A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Molecular Partners AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF3.40 |
52 Week High | CHF6.17 |
52 Week Low | CHF3.04 |
Beta | 0.80 |
1 Month Change | 0% |
3 Month Change | -6.08% |
1 Year Change | -44.89% |
3 Year Change | -85.28% |
5 Year Change | -78.80% |
Change since IPO | -84.82% |
Recent News & Updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation
Apr 11Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?
Jan 09Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation
Sep 08Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023
Jun 23What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today
Aug 31Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
May 09Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts
Dec 26We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely
Jun 24Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability
Mar 09Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts
Feb 10Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
Jan 21How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?
Dec 17Downgrade: Here's How Analysts See Molecular Partners AG (VTX:MOLN) Performing In The Near Term
Nov 21Shareholder Returns
MOLN | CH Biotechs | CH Market | |
---|---|---|---|
7D | 1.5% | 9.2% | 0.03% |
1Y | -44.9% | 35.0% | 2.2% |
Return vs Industry: MOLN underperformed the Swiss Biotechs industry which returned 35% over the past year.
Return vs Market: MOLN underperformed the Swiss Market which returned 2.2% over the past year.
Price Volatility
MOLN volatility | |
---|---|
MOLN Average Weekly Movement | 7.7% |
Biotechs Industry Average Movement | 7.7% |
Market Average Movement | 3.4% |
10% most volatile stocks in CH Market | 7.3% |
10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: MOLN has not had significant price volatility in the past 3 months.
Volatility Over Time: MOLN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 168 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
MOLN fundamental statistics | |
---|---|
Market cap | CHF112.82m |
Earnings (TTM) | -CHF58.53m |
Revenue (TTM) | CHF6.73m |
16.8x
P/S Ratio-1.9x
P/E RatioIs MOLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MOLN income statement (TTM) | |
---|---|
Revenue | CHF6.73m |
Cost of Revenue | CHF47.84m |
Gross Profit | -CHF41.12m |
Other Expenses | CHF17.41m |
Earnings | -CHF58.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 26, 2024
Earnings per share (EPS) | -1.76 |
Gross Margin | -611.33% |
Net Profit Margin | -870.22% |
Debt/Equity Ratio | 0% |
How did MOLN perform over the long term?
See historical performance and comparison